公司概覽
業務類別 --
業務概覽 Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
公司地址 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
電話號碼 +61 396396036
傳真號碼 +61 396396030
公司網頁 https://www.mesoblast.com
員工數量 108
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Eric A. Rose, M.D. Director and Chief Medical Officer 澳元 701.84K 27/08/2026
Dr. Silviu Itescu, F.A.C.P.,F.R.A.C.P. Director and Chief Executive Officer 澳元 757.50K 27/08/2026
Mr. Michael Schuster, M.B.A. Pharma Partnering -- 27/08/2026
Dr. Paul Simmons, PhD Scientific Advisor to the Chief Executive Officer -- 27/08/2026
Ms. Geraldine Storton, B.Sc. ,M.B.A. Head of Regulatory Affairs and Quality Management -- 27/08/2026
Ms. Niva Sivakumar, B.Com,L.L.B. Joint Company Secretary -- 27/08/2026
Mr. Justin Horst, B.S. Head of Manufacturing -- 27/08/2026
Mr. Paul Hughes, B.Bus Joint Company Secretary -- 27/08/2026
Dr. Fiona See, PhD Senior Vice President and Head of Translational Research -- 27/08/2026
Mr. James O'Brien, M.B.A. Chief Financial Officer -- 27/08/2026
 
董事會成員
董事會 職務 更新日期
Dr. Eric A. Rose, M.D. Director and Chief Medical Officer 27/08/2026
Mr. William J. Burns, B.A. Vice Chairman of the Board 27/08/2026
Mr. Philip J. Facchina Chairman of the Board 27/08/2026
Ms. Lyn Cobley, BEc Independent Director 27/08/2026
Dr. Silviu Itescu, F.A.C.P.,F.R.A.C.P. Director and Chief Executive Officer 27/08/2026
Mr. Philip Krause, M.D. Director 27/08/2026
Ms. Jane Bell, L.L.B.,L.L.M. Independent Director 27/08/2026
Dr. Gregory George, M.D. Director 27/08/2026
 
所屬ETF (更新日期: 19/09/2026 02:00)
代號 名稱 佔比% ▼ 持有日期
IEFAiShares Core MSCI EAFE ETF0.53%31/08/2026
SCZiShares MSCI EAFE Small-Cap ETF0.22%31/08/2026
SCHCSchwab International Small-Cap Eq ETF™0.13%29/08/2026
DFISDimensional International Small Cap ETF0.10%31/08/2026
IDEViShares Core MSCI Intl Dev Mkts ETF0.10%31/08/2026
SPDWState Street® SPDR® Ptf Dev Wld exUS ETF0.09%31/08/2026
DFICDimensional International Core Eq 2 ETF0.06%31/08/2026
IXUSiShares Core MSCI Total Intl Stk ETF0.06%31/08/2026
VTVanguard Total World Stock ETF0.05%31/08/2026
DFAIDimensional International Cr Eq Mkt ETF0.03%31/08/2026
DFAXDimensional World ex US Core Eq 2 ETF0.03%31/08/2026
IPACiShares Core MSCI Pacific ETF0.02%31/08/2026
VSGXVanguard ESG International Stock ETF0.01%31/08/2026
AVDSAvantis International Small Cp Eq ETF0.01%31/08/2026
GINNGoldman Sachs Innovate Equity ETF0.01%31/08/2026
WSMLiShares MSCI World Small-Cap ETF0.004%31/08/2026
DFSIDimensional International Sstby Cr 1 ETF0.003%31/08/2026
SPGMState Street® SPDR® Ptf MSCIGlbStkMktETF0.002%31/08/2026
TLTDNorthern Trust MstarDevMktsexUSFacTltETF0.002%31/08/2026
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.